Among all patients, pCR rate was 31.7% (365/1150) with significantly different rates according to tumor subtypes: 7.1%, 9.6%, 21.9%, 23.0%, and 38.1% for Luminal A, Luminal B‐like HER2‐negative, Luminal B‐like HER2‐positive, HER2‐positive, and TN tumors, respectively, and with significant rates according to cN stages (35.9% and 28.7% for cN0 and cN1, respectively) (Table 1). Here, ERBB2 is linked to neoplasm.